Last reviewed · How we verify
NCT07325643
Effect of Hydroxyapatite Toothpaste and Mouthwash in Preventing White Spot Lesions During Orthodontic Treatment
NA trial testing Hydroxyapatite Toothpaste in Prevention of White Spot Lesions in Patients Undergoing Orthodontic Treatment in 75 participants. Currently enrolling.
20 November 2026
Quick facts
| Lead sponsor | Heba Tahseen Almasri |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | prevention |
| Enrollment | 75 |
| Start date | 20 November 2025 |
| Primary completion | 20 November 2026 |
| Estimated completion | 20 December 2026 |
| Sites | 1 location across Iraq |
Drugs / interventions tested
- Hydroxyapatite Toothpaste
- Hydroxyapatite Mouthwash
- Fluoride Toothpaste + Placebo Mouthwash
Conditions studied
- Prevention of White Spot Lesions in Patients Undergoing Orthodontic Treatment — all drugs for Prevention of White Spot Lesions in Patients Undergoing Orthodontic Treatment →
Sponsor
Heba Tahseen Almasri
Who can join
Eligibility, any sex, with Prevention of White Spot Lesions in Patients Undergoing Orthodontic Treatment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to evaluate the effect of hydroxyapatite-containing toothpaste and mouthwash in preventing white spot lesions in patients undergoing orthodontic treatment. Participants: 75 patients will be divided into three groups: * Group A: Participants will brush their teeth three times a day using hydroxyapatite toothpaste and rinse twice a day with a placebo mouthwash. * Group B: Participants will brush their teeth three times a day using fluoride toothpaste and rinse twice a day with hydroxyapatite mouthwash. * Group C (Control Group): Participants will brush their teeth three times a day using fluoride toothpaste and rinse twice a day with a placebo mouthwash. Patients will be followed during their orthodontic treatment to assess the development of white spot lesions. The study is safe and involves no surgical procedures or risky medications, and will be conducted under the supervision of Principal Investigator Heba Masri after obtaining ethical approval.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07325643
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07325643 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Heba Tahseen Almasri
- Last refreshed: 8 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07325643.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing